Gamma-aminobutyric acid receptor subunit beta-1 (GABRB1)

Gamma-aminobutyric acid receptor subunit beta-1 (GABRB1) is a protein encoded by the GABRB1 gene in humans and forms part of the heteropentameric GABA(A) receptor complex, which functions as a ligand-gated chloride channel mediating the primary fast inhibitory synaptic transmission in the central nervous system[1][3][4][5]. The GABA(A) receptor is composed of various subunits including alpha, beta, and gamma isoforms, with the beta-1 subunit crucial for receptor assembly and function[4]. Upon GABA binding (at the α/β interface), the channel opens, allowing chloride influx into neurons, resulting in membrane hyperpolarization and reduced excitability[1][2][4]. Modulation of GABRB1-containing receptors by drugs such as benzodiazepines, barbiturates, neurosteroids, and general anesthetics underlies their clinical action in sedation, anxiolysis, anesthesia, and anticonvulsant therapy[1][4]. Mutations have been linked to severe epilepsy syndromes (DEE45/EIEE45), schizophrenia, and alcohol-related behaviors[3][4]. The molecular structure includes four transmembrane domains, with key regulatory and interaction regions influencing trafficking, pharmacological properties, and post-translational modifications[2][5]. GABRB1 is a valid therapeutic target and central to CNS pharmacology, but modulation presents safety and abuse challenges.

Other names

GABA(A) receptor subunit beta-1GABAAR subunit beta-1Gamma-aminobutyric acid type A receptor subunit beta1GABAA receptor subunit beta-1GABA(A) receptor, beta 1Gamma-aminobutyric acid (GABA) A receptor, beta 1DEE45EIEE45

Positive allosteric modulation (benzodiazepines increase channel opening); Direct agonism (GABA binds at α/β subunit interface to activate channel); Negative allosteric modulation (certain drugs or toxins inhibit channel function)